MedTrace Logo

Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1

NCT05520970 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2023-06-22

No results posted yet for this study

Summary

The immunogenicity and safety profiles of AdCLD-CoV19-1 (5.0×10\^10 VP/dose) will be assessed for 1-dose or 2-dose regimen in SARS-CoV-2 seronegative healthy adults.

Conditions

Interventions

BIOLOGICAL

AdCLD-CoV19-1

All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region

Sponsors & Collaborators

  • International Vaccine Institute

    collaborator OTHER

  • Cellid Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-19
Primary Completion
2022-11-08
Completion
2022-11-08

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05520970 on ClinicalTrials.gov